Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKosuke MikiKWKentaro WakasaTSTsuyoshi Sato

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals that ≥1% circulating plasma cells worsens prognosis in multiple myeloma patients, indicating a need for revised diagnostic criteria.

Key Points

  • Patients with ≥1% circulating plasma cells had significantly lower overall survival compared to those with <1%.
  • Median overall survival was 37.9 months with ≥1% circulating plasma cells versus 98.7 months with <1%.
  • The analysis focused on NDMM patients, assessing treatment regimens and outcomes based on plasma cell levels.
  • Identifying key thresholds for plasma cell count may lead to better risk stratification for multiple myeloma patients.

Cite This Study

Miki et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7cdhttps://doi.org/10.1182/blood-2025-2205
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients2025
  2. 2Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma2025
  3. 3Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  4. 4Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma2025
  5. 5Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents2025